Navigation Links
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for Asthma or Allergies without Trying First-Line Medications End Up Staying on the Medication
Date:4/27/2011

ST. PAUL, Minn., April 27, 2011 /PRNewswire/ -- Patients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair®) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether, according to a new study presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn. The study will be presented by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.

Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. Typical first-line therapies are inhaled corticosteroids for asthma and nasal steroids for allergic rhinitis. The inhaled steroids act locally by concentrating their effects directly within the breathing passages, with very few side effects outside of the lungs or sinuses.

For the study, researchers identified 907 individuals with asthma who filled a claim for newly initiated montelukast therapy in the fourth quarter of 2009. An additional 373 people with allergic rhinitis or allergies who initiated montelukast therapy during the same time period were also identified. Patients were followed for 120 days after their first claim was filled to assess whether they continued to take montelukast after 30, 60, 90 and 120 days.

At 120 days after initiating montelukast therapy, 30.9 percent of asthma patients still had a supply of this medication. A similar poor persistence on montelukast treatment at 120 days was noted in patients with allergic rhinitis. In addition, at 120 days after montelukast was initiated, the vast majority of asthma and allergic rhinitis patients were lacking any therapy (62.6 and 64.9 percent, respectively).

"Continued drug treatment is essential for managing asthma," said
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP-WHO Study
2. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... HARRISBURG, Pa. , Dec. 24, 2014  Commonwealth Cornerstone ... New Markets Tax Credits transaction on Tuesday to help fund ... Health Network (PHN) in Sharon . ... operating in Pennsylvania . It is the ... district, with more than 150 people on staff. ...
(Date:12/24/2014)... 2014 Kinex Pharmaceuticals announced today that the ... Park Cancer Institute. KX2-361 (KX02), a dual ... shown potent inhibitory activity against a broad panel of ... to Temozolomide (T98G), the most widely used chemotherapy for ... tumor mouse model, KX2-361 consistently clears brain tumors after ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... 2011 For the second year in a row Royce ... Associates, received a supplier recognition from Carestream Health, the world,s ... Carestream Health, which supplies a complete line of Medical and ... Royce their 2010 Supplier of the Year , Carestream,s ...
... 2011 Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for ... update. First Quarter Financial Results ... $7.5 million, an increase of 37 percent compared with $5.4 million ... or 56 percent of net sales, compared with gross profit of ...
Cached Medicine Technology:Royce Receives Coveted Medical Products Award 2Transgenomic Reports First Quarter Financial Results 2Transgenomic Reports First Quarter Financial Results 3Transgenomic Reports First Quarter Financial Results 4Transgenomic Reports First Quarter Financial Results 5Transgenomic Reports First Quarter Financial Results 6Transgenomic Reports First Quarter Financial Results 7Transgenomic Reports First Quarter Financial Results 8Transgenomic Reports First Quarter Financial Results 9
(Date:12/26/2014)... California (PRWEB) December 26, 2014 Plugin and ... the TransPack Volume 5 Plugin for Final Cut Pro X. ... a hard light tool to pull off an industry professional ... users get their hands on TransPack Volume 5, a new ... 5 is a set of over 50 Final Cut Pro ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... recent increase in the number of men who are going under ... of men undergoing nip and tuck surgery has rocketed by 140 ... ,The phenomenon has been dubbed the 'menopaunch' as men fork ... to be facing pressures as women to look good thus they ...
... and body, a rare medical anomaly. And doctors say that laser ... ,Prithviraj Patil, son of a well-to-do farmer in Sangalwadi near ... like any normal child. ,,Prithiviraj has no problem with his ... awful - there is no itch or rash on the skin ...
... A type of skin cancer that was rare three decades ... the Journal of the American Medical Association (JAMA) found . ... increasingly more common in the United States in the decades ... July issue of Archives of Dermatology, which is part of ...
... on a teenager from wearing a so-called "purity ring" at school ... ,Lydia Playfoot, 16, said she was "disappointed" by the ruling in ... West Sussex, denies infringing her human rights, saying that the ring ... its uniform policy. ,"As a Christian I do not ...
... could dramatically lower the rapidly rising costs of several ... specialists suggest in a commentary in the Journal ... Mark Ratain, MD, and Ezra Cohen, MD, call attention ... certain foods can alter absorption or delay breakdown of ...
... is a universal problem that doctors need to ... Wake Forest University School of Medicine in ... Archives of Dermatology. ,He said non-compliance ... to treatment. ,Physicians must develop practical ...
Cached Medicine News:Health News:Men Under Knife to Reduce Bulging Waistline in Britian 2Health News:Hairy Boy Bets on Laser Treatment for Cure 2Health News:Value Meal Would Lower Drug Costs 2Health News:Value Meal Would Lower Drug Costs 3Health News:Patients Not Complying With Their Dermatologic Problem 2Health News:Patients Not Complying With Their Dermatologic Problem 3
... Malaria Test is a field or laboratory test ... It is intended for the detection of circulating ... antigen that is common to all four species ... Plasmodium vivax (P.v.), Plasmodium ovale ...
Hypervisor III Central Monitoring System...
DS 5700 New Central Station...
... Alaris System integrates drug infusion,with patient ... a single, modular platform. With multiple ... modules as you,need them, keeping the ... a minimum while managing the unique ...
Medicine Products: